Loading policy item
SB 1528
This proposal did not become law. SB 1528 A-Engrossed would have replaced a study bill with substantive reporting requirements, mandating drug manufacturers to annually disclose detailed data on all patient assistance programs serving Oregon consumers, including participation counts, total subsidy values, and eligibility criteria, effective January 1, 2028.
Generated explanation · A-Engrossed · Analyzed 8/20/2026 · Open official A-Engrossed text
This proposal did not become law.
Generated analysis of A-Engrossed text; it does not establish that the bill applies to you. Read the full decision brief.
No upcoming event is verified in the available records.
Plain-language analysis
Generated analysis, not an official summary or legal advice. Confirm with linked Oregon documents.
This proposal did not become law. The generated effects below describe what it would have required if enacted.
SB 1528 A-Engrossed would have replaced a study bill with substantive reporting requirements, mandating drug manufacturers to annually disclose detailed data on all patient assistance programs serving Oregon consumers, including participation counts, total subsidy values, and eligibility criteria, effective January 1, 2028.
Basis: Bill text · Sources: A-Engrossed; Staff Measure Summary A
Oregon's Prescription Drug Price Transparency program recommended in its 2025 report that manufacturers be required to report annually on all patient assistance programs they maintain or fund.
Basis: Official analysis · Source: Staff Measure Summary A
Inferred from cited text; not a stated purpose.
The requirement to report total value of assistance, eligibility criteria, and verification methods suggests an objective to increase transparency regarding the net cost to consumers and the scope of manufacturer subsidies, potentially to inform future affordability policies or detect pricing structures where high list prices are offset by coupons.
Basis: Inferred · Source: A-Engrossed
Would have had to collect and report granular data on all patient assistance programs, including participation numbers, total value of coupons/discounts/copay assistance, refills, program duration, and eligibility criteria. Subject to civil penalties for non-compliance.
Basis: Bill text · Source: A-Engrossed
Potential effect if enacted: Indirect benefit through enhanced state visibility into assistance programs; gain access to a notification process for price increases. Personally identifiable information in notifications is confidential.
Basis: Bill text · Source: A-Engrossed
Receives and verifies manufacturer reports; might have requested additional documentation; posts non-exempt information to its website; would have provided data to the Prescription Drug Affordability Board.
Basis: Bill text · Source: A-Engrossed
Potential effect if enacted: Receives annual compiled reports and recommendations from DCBS regarding drug costs; no longer the primary entity conducting a standalone study as in the introduced version.
Basis: Bill text · Source: A-Engrossed
Manufacturers would have had to implement systems to track patient assistance program participation by Oregon residents and aggregate data on total subsidy values. The measure has minimal fiscal impact on state government expenditures but would have imposed compliance costs on the private sector.
Basis: Bill text · Sources: A-Engrossed; Fiscal Impact Statement A
Potential effect if enacted: DCBS gains authority to verify reported information and request supporting documentation, with defined response periods. Manufacturers face civil penalties for failing to submit timely reports or providing inaccurate information.
Basis: Bill text · Source: A-Engrossed
Information reported by manufacturers might have been posted publicly unless conditionally exempt as a trade secret, subject to public interest balancing and Attorney General review petitions.
Basis: Bill text · Source: A-Engrossed
Low-income consumers and policymakers
Potential effect if enacted: A manufacturer with a high-cost specialty drug uses complex patient assistance programs to obscure the true net cost to low-income patients. The new reporting requirements force disclosure of total subsidy values and eligibility criteria, revealing that the drug is effectively free for many via coupons. This data enables policymakers to adjust affordability metrics, negotiate better rates based on actual net costs, or identify artificial price inflation masked by subsidies.
Basis: Inferred · Source: A-Engrossed
Small or niche drug manufacturers
Potential effect if enacted: A manufacturer with a low-volume specialty drug has a simple patient assistance program. The cost of building systems to track 'consumers residing in this state' and report granular data (eligibility, refills, total value) exceeds the revenue from Oregon sales. The manufacturer withdraws the drug from the Oregon market or exits entirely, reducing consumer access.
Basis: Inferred · Source: A-Engrossed
The text would have allowed manufacturers to report 'total value' and 'eligibility criteria,' which relies on self-reporting. Without robust verification of residency or program mechanics, data integrity might have been compromised. The trade secret exemption would have required a balancing test, but weak enforcement could have allowed overclaiming.
Sources · A-Engrossed
Potential effect if enacted: The measure trades increased regulatory compliance burdens and data collection obligations on drug manufacturers for enhanced state visibility into the scope, value, and eligibility of patient assistance programs that subsidize prescription drug costs.
Would have provided policymakers with comprehensive data on manufacturer subsidies, enabling more informed decisions on affordability, pricing transparency, and potential regulatory interventions.
Basis: Inferred · Source: A-Engrossed
Potential effect if enacted: Increases public transparency regarding how much out-of-pocket costs are reduced by manufacturer coupons and assistance programs.
Basis: Inferred · Source: A-Engrossed
Would have imposed administrative and data-tracking costs on manufacturers, which might have been disproportionate for small companies or low-volume drugs.
Basis: Inferred · Source: A-Engrossed
Reliance on manufacturer self-reporting and potential trade secret claims might have limited the utility of disclosed data if verification is insufficient or exemptions are overused.
Basis: Inferred · Source: A-Engrossed
The introduced version required the Oregon Health Authority to conduct a study of health care and submit findings by September 15, 2027. The A-Engrossed version replaces the study with substantive amendments to ORS 646A.689, expanding annual reporting obligations for drug manufacturers under the Department of Consumer and Business Services to include detailed patient assistance program data.
Replaces OHA study requirement with manufacturer reporting requirements administered by DCBS.
shifts from legislative study to regulatory reporting framework.
Sources · Introduced; A-Engrossed
Adds requirement for manufacturers to report on all patient assistance programs serving Oregon consumers, including participation numbers, total subsidy values, and eligibility criteria.
expands transparency scope beyond price increases to include manufacturer subsidies.
Sources · A-Engrossed
Explicitly subjects manufacturers to civil penalties for non-compliance with reporting and documentation requests.
adds enforcement mechanism absent in the study bill.
Sources · A-Engrossed
Operative date set to January 1, 2028; no revenue impact identified.
implementation timeline and fiscal neutrality confirmed.
Sources · A-Engrossed; Revenue Impact Statement A
Tradeoff: The measure shifts from a passive study to active reporting, trading manufacturer compliance costs for enhanced state data on patient assistance programs.
Model self-rating: high. The bill text is explicit regarding reporting requirements, triggers, and operative date. Official supporting sources confirm the rationale and fiscal impact. Inferences are bounded by the text and labeled as such. This is the model’s assessment of its own analysis, not independent verification or human review.
Possible effects if adopted; not current bill text.
This proposal has not become law. The generated effects below describe what it would require if enacted.
The measure would expand Oregon’s prescription drug price transparency framework by requiring manufacturers to annually report comprehensive data on all patient assistance programs (PAPs) serving Oregon residents, regardless of whether the associated drugs triggered standard price-increase reporting thresholds. This would create a state-maintained public database of manufacturer financial aid metrics that would inform legislative recommendations to contain drug costs and reduce consumer out-of-pocket burdens.
Basis: Inferred · Sources: Senate Amendments to Introduced; Staff Measure Summary A
The measure responds to a specific recommendation in the 2025 legislative report from Oregon’s Prescription Drug Price Transparency program, which advised requiring manufacturers to report annually on all patient assistance programs they maintain or fund.
Basis: Official analysis · Source: Staff Measure Summary A
Inferred from cited text; not a stated purpose.
The amendment removes the prior limitation tying PAP reporting only to drugs that triggered price-increase thresholds, suggesting a legislative intent to capture the full scope of manufacturer-sponsored financial aid programs that may offset high drug prices and obscure true net costs.
Basis: Inferred · Sources: Senate Amendments to Introduced; A-Engrossed
Would have to collect and report granular PAP data annually by March 15, including participation counts, total discount values, refill eligibility, program duration, and verification criteria. Civil penalties apply for late, missing, inaccurate, or unresponsive reporting.
Basis: Inferred · Source: Senate Amendments to Introduced
Potential effect if enacted: Gain access to a public state database detailing manufacturer financial assistance programs, potentially improving transparency about out-of-pocket cost reductions, program expiration dates, and eligibility hurdles.
Basis: Inferred · Source: Senate Amendments to Introduced
Potential effect if enacted: Bears administrative responsibility to receive reports, verify data, manage trade secret exemptions, publish information online, and compile annual legislative recommendations.
Basis: Inferred · Source: Senate Amendments to Introduced
Potential effect if enacted: Receive expanded pricing and PAP data to inform future policy recommendations on drug affordability, commercial insurance premiums, and public program costs.
Basis: Inferred · Source: Senate Amendments to Introduced
Manufacturers face new compliance costs for data aggregation across all PAPs, even those not tied to price-increase triggers. DCBS incurs minimal fiscal impact per official analysis but would have to allocate staff for verification and publication.
Basis: Inferred · Sources: Fiscal Impact Statement A; IS_Impact SB 1528 2
Potential effect if enacted: Public website publication of PAP metrics may alter consumer behavior by revealing program limitations, while manufacturers may face reputational or market pressure if data shows limited assistance or high profit margins relative to costs.
Basis: Inferred · Source: Senate Amendments to Introduced
Potential effect if enacted: DCBS gains authority to request additional documentation and set response timelines by rule, with civil penalties enforceable under existing statute for noncompliance.
Basis: Inferred · Source: Senate Amendments to Introduced
Low-income patients on high-cost specialty drugs
Potential effect if enacted: Reported PAP data demonstrates that manufacturer assistance effectively caps out-of-pocket costs at $0 for eligible enrollees, prompting legislative action to expand state-subsidized coverage and align public programs with manufacturer aid thresholds.
Basis: Inferred · Source: Senate Amendments to Introduced
Manufacturers with complex PAP structures
Potential effect if enacted: A manufacturer faces severe civil penalties and public disclosure of trade-secret pricing methodologies after failing to meet DCBS documentation requests, forcing the company to withdraw the program from Oregon entirely and leaving patients with unaffordable full-price drugs.
Basis: Inferred · Source: Senate Amendments to Introduced
Potential effect if enacted: inference
Sources · Senate Amendments to Introduced
Expanding PAP reporting captures comprehensive financial aid data to inform affordability policy but would impose compliance burdens on manufacturers and risks reduced transparency if trade secret exemptions are broadly applied.
Potential effect if enacted: Granular visibility into patient assistance programs enables targeted legislative cost-containment tools.
Basis: Inferred · Source: Staff Measure Summary A
Potential effect if enacted: Public data disclosure may pressure manufacturers to align assistance programs with consumer needs and reduce opaque pricing practices.
Basis: Inferred · Source: Senate Amendments to Introduced
Potential effect if enacted: Administrative and data-aggregation costs for DCBS and manufacturers, despite minimal direct fiscal impact.
Basis: Inferred · Source: Fiscal Impact Statement A
Potential effect if enacted: Manufacturers may restrict or withdraw PAPs from Oregon if compliance complexity or privacy concerns outweigh program viability.
Basis: Inferred · Source: Senate Amendments to Introduced
Model self-rating: high. Analysis is grounded in official legislative revenue, fiscal, and staff analysis documents alongside the exact published bill text. No external speculation or unverified claims are included. This is the model’s assessment of its own analysis, not independent verification or human review.
This proposal has not become law. The generated effects below describe what it would require if enacted.
If adopted, this amendment would replace the original study-focused bill with substantive Medicaid drug purchasing reforms. It would legally mandate the Oregon Health Authority (OHA) to secure the lowest net cost for prescription drugs across all medical assistance programs, establish a new advisory cooperative, authorize OHA to use a third-party purchasing agent, expand OHA’s authority to negotiate supplemental rebates and join multistate purchasing pools, and delay certain existing statutory effective dates. Potential effects could include centralized procurement authority, potential shifts in formulary access and out-of-pocket costs for medical assistance recipients, new annual reporting obligations, and altered negotiation dynamics with pharmaceutical manufacturers.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Official sources do not state why this measure was proposed.
Sponsor testimony, staff summaries, committee materials, or statutory findings may explain it.
Inferred from cited text; not a stated purpose.
The amendment likely aims to implement a specific recommendation from Oregon’s Prescription Drug Price Transparency program to centralize Medicaid drug purchasing and leverage bulk negotiation for cost savings.
Basis: Inferred · Source: Staff Measure Summary A
Potential effect if enacted: Gains statutory mandate to negotiate supplemental rebates, contract with a third-party purchasing agent, appoint cooperative members, and submit annual reports on drug costs and preferred drug list alignment.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Potential effect if enacted: Subject to OHA’s centralized drug pricing and formulary alignment; may experience altered out-of-pocket costs, changed formulary access, or premium impacts depending on negotiated rebate outcomes.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Potential effect if enacted: Included in the lowest-cost purchasing mandate, potentially altering their drug coverage terms and procurement pathways.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Potential effect if enacted: Face new statutory obligation to negotiate supplemental rebates with OHA and potentially multistate pools beyond federal requirements.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Potential effect if enacted: Appointed volunteers tasked with advising on drug pricing, rebate leverage, and formulary alignment, serving at the pleasure of the OHA Director without compensation.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
OHA would have to appoint cooperative members by January 1, 2027, implement lowest-cost purchasing steps by January 1, 2028, and submit annual reports on rebates, savings, and preferred drug list alignment. Manufacturers would have to engage in supplemental rebate negotiations.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Shifts procurement risk to OHA; may reduce state drug expenditures but would require administrative infrastructure for the cooperative and purchasing agent. Formulary changes could alter eligibility or access pathways for specific drugs.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Annual reporting would create transparency, while executive session provisions allow confidential commercial discussions, potentially limiting public scrutiny of specific contract terms.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
State Budget and Medical Assistance Recipients
Potential effect if enacted: OHA successfully leverages multistate pooling and supplemental rebates to reduce Medicaid drug expenditures by 15–20%, significantly lowering state budget pressure and stabilizing CCO premiums for medical assistance recipients.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Providers and Recipients of Specialized Medications
The third-party purchasing agent fails to secure competitive rates, or the cooperative’s advisory role would create bureaucratic delays that restrict formulary access for rare or complex drugs, forcing providers to seek costly prior authorizations or alternative coverage pathways.
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Potential effect if enacted: The distinction rests on whether executive session use remains narrowly tailored to legitimate commercial confidentiality versus expanding into routine procurement decisions that should remain publicly documented.
Sources · Amendment -MR5 — proposed amendment
Potential effect if enacted: Centralizing drug purchasing authority and leveraging supplemental rebates may lower state costs and stabilize recipient premiums, but it concentrates procurement power in OHA and a new advisory body, potentially reducing market competition and limiting direct formulary control for CCOs and providers.
Potential effect if enacted: Potential for significant state cost savings through bulk negotiation and multistate pooling
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Potential effect if enacted: Standardized drug pricing across medical assistance programs may reduce administrative complexity
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Potential effect if enacted: Mandated annual reporting increases transparency on rebate collections and savings
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Potential effect if enacted: Concentrated procurement power may reduce manufacturer competition or innovation incentives
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Potential effect if enacted: CCOs lose direct formulary control, potentially creating access delays for specialized medications
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Potential effect if enacted: Executive session provisions limit public oversight of confidential contract terms
Basis: Inferred · Source: Amendment -MR5 — proposed amendment
Model self-rating: high. Analysis is strictly grounded in the supplied proposed amendment text and official committee/fiscal documents. All claims are bounded by statutory language and explicitly labeled as inferences where applicable. This is the model’s assessment of its own analysis, not independent verification or human review.
This proposal has not become law. The generated effects below describe what it would require if enacted.
The amendment would replace SB 1528's study requirement with technical amendments to existing Oregon Laws 2023. It delays the operative date of ORS 441.765 by one year (to July 1, 2027), sets the operative date of ORS 653.258 and related wage/hour provisions to June 1, 2025, and would authorize the Bureau of Labor and Industries Commissioner to take necessary actions before that date.
Basis: Stakeholder claim · Source: Amendment -3 — proposed amendment
Official sources do not state why this measure was proposed.
Sponsor testimony, staff summaries, committee materials, or statutory findings may explain it.
Inferred from cited text; not a stated purpose.
The amendment likely corrects a statutory implementation gap or misalignment by extending the timeline for health care regulatory duties while establishing a definitive start date for labor provisions and allowing early administrative preparation.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Potential effect if enacted: OHA's authority under ORS 441.765 is delayed until July 1, 2027, preventing the exercise of statutory duties during the intervening period.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Potential effect if enacted: BOLI gains authority to take pre-implementation actions before June 1, 2025, and assumes full duties under ORS 653.258 and amendments to ORS 653.261 on that date.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Potential effect if enacted: Compliance, licensing, or regulatory requirements tied to this statute are postponed until July 1, 2027.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Potential effect if enacted: Provisions become operative on June 1, 2025; BOLI may enforce or regulate related matters before this date if deemed necessary.
Basis: Inferred · Source: Amendment -3 — proposed amendment
OHA would have to defer all implementation activities for ORS 441.765 until July 1, 2027, potentially affecting budgeting, staffing, and regulatory timelines.
Basis: Inferred · Source: Amendment -3 — proposed amendment
BOLI could initiate preparatory work for ORS 653.258 immediately or before June 1, 2025, without waiting for the operative date.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Potential effect if enacted: The amendment has minimal fiscal impact on state or local government expenditures and no revenue impact.
Basis: Stakeholder claim · Sources: Fiscal Impact Statement A; Revenue Impact Statement A
BOLI and labor market participants
Potential effect if enacted: BOLI uses pre-implementation authority to establish critical wage enforcement mechanisms or guidance before June 1, 2025, preventing a gap in worker protections and ensuring immediate compliance readiness.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Health care consumers and regulated entities
Potential effect if enacted: The one-year delay for ORS 441.765 postpones essential health care regulatory oversight or licensing requirements, leaving a regulatory vacuum or delaying consumer protections until July 2027.
Basis: Inferred · Source: Amendment -3 — proposed amendment
The text would grant broad pre-implementation authority without defining limits on enforcement versus preparation.
Sources · Amendment -3 — proposed amendment
Potential effect if enacted: The measure trades an additional year of delay for health care regulatory implementation under ORS 441.765 against early administrative preparation and a confirmed June 2025 start for labor provisions under ORS 653.258.
Would allow BOLI to prepare effectively for labor provisions, reducing implementation risk.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Potential effect if enacted: Confirms a definitive operative date for ORS 653.258, providing certainty for employers and employees.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Potential effect if enacted: Postpones health care statutory duties by one year, potentially delaying intended consumer protections or oversight.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Potential effect if enacted: Broad pre-implementation authority for BOLI may create uncertainty regarding the scope of permissible actions before June 1, 2025.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Model self-rating: high. The amendment text is explicit regarding operative dates and statutory references. Supporting sources confirm fiscal neutrality but contain unrelated content regarding drug reporting, which does not affect the analysis of the amendment's text. This is the model’s assessment of its own analysis, not independent verification or human review.
This proposal has not become law. The generated effects below describe what it would require if enacted.
The amendment would expand Oregon’s prescription drug price transparency program to require manufacturers to annually report detailed pricing, cost, revenue, and profit data for drugs with significant price increases, plus comprehensive reporting on all patient assistance programs serving Oregon consumers. It would establish a public disclosure framework with trade secret protections, would create civil penalties for noncompliance, and mandates an annual legislative report with recommendations to control drug costs.
Basis: Inferred · Source: Amendment -2 — proposed amendment
The measure responds to a 2025 legislative report recommendation requiring manufacturers to report annually on all patient assistance programs they maintain or fund.
Basis: Official analysis · Source: Staff Measure Summary A
Inferred from cited text; not a stated purpose.
Expanding reporting to cover all patient assistance programs regardless of price triggers suggests an intent to close transparency gaps where discount programs might obscure net prices or limit the apparent impact of price increases on consumers.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Would have to collect, verify, and submit extensive financial, pricing, and program data annually or upon new drug introduction; face civil penalties for noncompliance.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Potential effect if enacted: Gains administrative authority to receive reports, manage trade secret exemptions, post data publicly, request additional information, and compile annual legislative recommendations.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Gain access to aggregated pricing and assistance program data via public channels; could confidentially report price increases to the department.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Potential effect if enacted: Receive direct access to manufacturer financial data to inform policy or purchasing decisions.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Manufacturers would incur compliance costs for data aggregation, auditing, and reporting infrastructure aligned with department rules.
Basis: Inferred · Source: Amendment -2 — proposed amendment
The department would require administrative capacity to process reports, manage public posting, handle trade secret claims, and enforce penalties.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Consumers and policymakers would have standardized visibility into net drug costs after manufacturer discounts, potentially influencing purchasing decisions or insurance formulary placements.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Potential effect if enacted: While the measure incorporates federal definitions for pricing thresholds and drug classifications, the reporting obligations, enforcement mechanisms, and public disclosure rules remain strictly governed by Oregon state law.
Basis: Inferred · Source: Amendment -2 — proposed amendment
The January 1, 2028 operative date would allow manufacturers time to adjust reporting systems before enforcement begins.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Low-income Oregon consumers and state purchasing entities
Potential effect if enacted: A manufacturer with a high-cost specialty drug uses aggressive patient assistance programs that effectively reduce out-of-pocket costs to near zero for low-income patients; comprehensive reporting reveals the true gross price and discount volume, enabling policymakers to negotiate bulk purchasing or cap out-of-pocket expenses based on verified assistance data.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Small biotech or specialty drug manufacturers
Potential effect if enacted: A small firm faces prohibitive compliance costs to itemize public-funded research and development, direct marketing expenses, and international pricing for a niche drug with minimal Oregon sales; the threat of civil penalties for minor reporting discrepancies forces the firm to withdraw from the Oregon market or raise prices to offset administrative burdens.
Basis: Inferred · Source: Amendment -2 — proposed amendment
The text would legally permit manufacturers to claim trade secret exemptions under state law for submitted financial data. A potential unlawful outcome could arise if manufacturers systematically overclaim exemptions to shield competitive pricing strategies, relying on weak department review or delayed attorney general petition processes to maintain opacity. Conversely, the department could misclassify legitimate public interest disclosures as exempt, chilling transparency.
Sources · Amendment -2 — proposed amendment
Potential effect if enacted: The measure trades increased manufacturer compliance burdens and potential market withdrawal for niche drugs against greater consumer and policymaker visibility into net drug costs and discount program usage. Upsides include informed purchasing decisions and targeted cost-containment policies; downsides include administrative costs, possible reduced access to specialized medications, and reliance on effective enforcement of trade secret protections.
Potential effect if enacted: Standardized visibility into net drug costs after manufacturer discounts, potentially influencing purchasing decisions or insurance formulary placements.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Potential effect if enacted: Targeted cost-containment policies based on verified assistance program data and legislative recommendations.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Potential effect if enacted: Administrative costs for manufacturers and the department to process reports, manage public posting, handle trade secret claims, and enforce penalties.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Potential effect if enacted: Possible reduced access to specialized medications if small firms withdraw from the Oregon market or raise prices to offset compliance burdens.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Potential effect if enacted: Reliance on effective enforcement of trade secret protections to prevent opacity or chilling of transparency.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Model self-rating: high. The amendment text is explicit regarding reporting triggers, data requirements, enforcement mechanisms, and operative dates. Official fiscal and staff analyses confirm minimal revenue impact and clarify the legislative recommendation driving the change. This is the model’s assessment of its own analysis, not independent verification or human review.
This proposal has not become law. The generated effects below describe what it would require if enacted.
The amendment would require prescription drug manufacturers selling in Oregon to annually report comprehensive data on all patient assistance programs (PAPs) serving state residents, regardless of whether a drug’s price increased. It would expand existing transparency mandates, would establish civil penalties for noncompliance, would require the Department of Consumer and Business Services (DCBS) to publicly post most submitted data (subject to trade secret exemptions), and would direct an annual legislative report with cost-containment recommendations.
Basis: Inferred · Source: Amendment -2 — proposed amendment
The measure responds to a 2025 recommendation from Oregon’s Prescription Drug Price Transparency program to require manufacturers to report annually on all PAPs they maintain or fund.
Basis: Official analysis · Source: Staff Measure Summary A
Inferred from cited text; not a stated purpose.
Lawmakers may be seeking to evaluate whether PAPs are effectively reducing consumer out-of-pocket costs or inadvertently masking underlying price increases, given the amendment’s focus on tracking program duration, eligibility verification, and total assistance value.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Would have to collect and submit granular PAP data annually by March 15, alongside existing price-increase and new-drug reporting obligations.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Potential effect if enacted: Bears administrative responsibility for verifying reports, managing public posting, adjudicating trade secret claims, and compiling annual legislative recommendations.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Potential effect if enacted: Gain access to standardized data on PAP eligibility, duration, and total assistance value, potentially improving program navigation and advocacy leverage.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Potential effect if enacted: Receive consolidated annual data and policy recommendations to inform future drug cost legislation.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Manufacturers would need internal compliance systems to track PAP participation, eligibility criteria, and financial assistance values across all Oregon patients.
Basis: Inferred · Source: Amendment -2 — proposed amendment
DCBS would have to develop verification protocols, a public data portal, and a process for handling trade secret petitions and Attorney General reviews.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Potential effect if enacted: Civil penalties under ORS 646A.692 apply to late, missing, or inaccurate submissions.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Potential effect if enacted: Public posting of PAP metrics may alter manufacturer program design or eligibility thresholds to avoid competitive scrutiny.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Oregon consumers and patients
Potential effect if enacted: Public disclosure reveals that a major manufacturer’s PAP excludes patients above 200% of the federal poverty level despite marketing claims of broad access; legislative committees use the data to mandate standardized eligibility tiers, reducing patient financial toxicity statewide.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Prescription drug manufacturers selling in Oregon
Potential effect if enacted: A manufacturer faces escalating civil penalties and protracted litigation over trade secret exemptions for proprietary pricing algorithms, ultimately withdrawing a specialty drug from the Oregon market or drastically curtailing PAP funding due to compliance costs and competitive exposure.
Basis: Inferred · Source: Amendment -2 — proposed amendment
The statutory exemption hinges on a public-interest balancing test that would lack objective thresholds, creating room for broad confidentiality claims to shield competitive pricing methodologies.
Sources · Amendment -2 — proposed amendment
Expanding PAP transparency increases market visibility and consumer protection but would impose significant administrative costs on manufacturers and state agencies while risking competitive harm through forced disclosure of proprietary program structures.
Potential effect if enacted: Standardized patient assistance access and data-driven cost-containment policy.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Potential effect if enacted: Enhanced legislative oversight of drug pricing and manufacturer discount practices.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Potential effect if enacted: Compliance burdens and potential trade secret litigation for manufacturers.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Potential effect if enacted: Possible manufacturer withdrawal or program restructuring to limit public exposure.
Basis: Inferred · Source: Amendment -2 — proposed amendment
Model self-rating: high. The amendment text is explicit regarding reporting triggers, required data fields, enforcement mechanisms, and public posting rules. Official fiscal and revenue impact statements confirm minimal state expenditure. Remaining uncertainty centers on implementation rules and industry response. This is the model’s assessment of its own analysis, not independent verification or human review.
This proposal has not become law. The generated effects below describe what it would require if enacted.
The proposed amendment would replace the original bill text with provisions that delay the operative date of prescription drug price transparency rules by one year to July 1, 2027, and sets the operative date for specific labor commissioner powers to June 1, 2025 while authorizing pre-emptive administrative preparation.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Official sources do not state why this measure was proposed.
Sponsor testimony, staff summaries, committee materials, or statutory findings may explain it.
Inferred from cited text; not a stated purpose.
The amendment may reflect a legislative adjustment to extend compliance timelines for drug manufacturers while correcting or validating the effective date of labor provisions, as indicated by the shift to a past operative date and the addition of preparatory authority for the Bureau of Labor and Industries.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Potential effect if enacted: Delayed compliance with ORS 441.765 provisions by one year, extending the timeline for implementing reporting or transparency requirements.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Potential effect if enacted: Postponed access to drug pricing transparency data mandated by the delayed provisions, potentially affecting cost awareness and market competition.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Potential effect if enacted: Granted authority to take preparatory actions before the June 1, 2025 operative date for ORS 653.258 and related amendments; subject to a past operative date that may require validation of prior administrative steps.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Potential effect if enacted: Adjusted timelines for implementing drug-related provisions, with no revenue impact noted.
Basis: Inferred · Sources: Amendment -3 — proposed amendment; Fiscal Impact Statement A
Potential effect if enacted: Manufacturers gain an additional year to align systems or policies with ORS 441.765 requirements, reducing immediate administrative burdens.
Basis: Inferred · Source: Amendment -3 — proposed amendment
BOLI could initiate rulemaking or administrative preparations immediately, ensuring readiness for the June 1, 2025 date, though the past operative date may necessitate retroactive validation of actions.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Potential effect if enacted: Fiscal impact is minimal per Legislative Revenue Office and Legislative Fiscal Office analyses, with no state or local revenue impact.
Basis: Stakeholder claim · Sources: IS_Impact SB 1528 2; Fiscal Impact Statement A
Drug manufacturers
Potential effect if enacted: A manufacturer avoids significant compliance costs by deferring implementation for a year, preserving capital during a period of market volatility or supply chain disruption.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Oregon consumers and workers
Consumers face prolonged exposure to opaque pricing structures due to the one-year delay, while BOLI's authority to act before the past operative date would create legal ambiguity that could be exploited to enforce unapproved policies or fail to address wage violations retroactively.
Basis: Inferred · Source: Amendment -3 — proposed amendment
The text would permit preparatory actions but does not authorize enforcement of substantive duties before the operative date; misuse would constitute duty creep beyond the scope of the amendment.
Sources · Amendment -3 — proposed amendment
Delaying drug transparency requirements would reduce immediate compliance burdens for manufacturers but postpones consumer access to pricing data that supports market competition and cost containment.
Extended timeline would allow manufacturers more time to implement complex reporting systems, potentially reducing errors and administrative costs.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Preparatory authority for BOLI ensures that labor provisions could be implemented smoothly when the operative date arrives.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Potential effect if enacted: Consumers and policymakers lose a year of drug pricing data, which may hinder efforts to contain costs and inform healthcare decisions.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Potential effect if enacted: Setting an operative date in the past may create legal uncertainty regarding when duties attach and how prior administrative actions are validated.
Basis: Inferred · Source: Amendment -3 — proposed amendment
Model self-rating: medium. The analysis is based on the proposed amendment text and supporting documents. The amendment replaces the original measure, but the full context of what was replaced is not fully detailed in the provided sources. The past operative date for labor provisions introduces legal complexity that requires further clarification. This is the model’s assessment of its own analysis, not independent verification or human review.
27 records currently loaded
Records available in the current snapshot.
Earliest loaded signal
Introduced bill text posted
Posted Jan 28, 2026, 3:25 PM PST
AI-assessed adopted replacement
The adopted rewrite removes the generic health-care study and substitutes operative drug-pricing transparency law.
AI assessment dated 2026-09-29. This classification is separate from enactment and legal effect.
Evidence snapshot: 2026-09-29. Later legislative records are not automatically reassessed.
Policy purpose: substantially changed.
Reviewer: /root/review_recent_a · 2026-09-29
AI-assessed adopted replacement
The adopted rewrite removes the generic health-care study and substitutes operative drug-pricing transparency law.
Policy purpose: substantially changed.
“SECTION 1. The Oregon Health Authority shall study health care. The authority shall 5 submit a report in the manner provided by ORS 192.245, and may include recommendations 6 for legislation, to the interim committees of the Legislative Assembly related to health care 7 no later than September 15, 2027. 8 SECTION 2. Se”
Introduced
“SECTION 1. ORS 646A.689 is amended to read: 5 646A.689. (1) As used in ORS 646A.680 to 646A.697: 6 (a) “Drug” has the meaning given that term in ORS 689.005. 7 (b) “Health care facility” has the meaning given that term in ORS 442.015. 8 (c) “Health care service contractor” has the meaning given that term in ORS 750”
A-Engrossed
Reviewer: /root/review_recent_b · 2026-09-29
AI-assessed adopted replacement
The adopted -2 amendment deletes the generic health study and imposes a new pharmaceutical transparency duty.
Policy purpose: substantially changed.
“SECTION 1. The Oregon Health Authority shall study health care. The authority shall 5 submit a report in the manner provided by ORS 192.245, and may include recommendations 6 for legislation, to the interim committees of the Legis”
Introduced
“SECTION 1. ORS 646A.689 is amended to read: 5 646A.689. (1) As used in ORS 646A.680 to 646A.697: 6 (a) “Drug” has the meaning given that term in ORS 689.005. 7 (b) “Health care facility” has the meaning given that term in ORS 442.015. 8 (c) “Health care service contractor” has the meaning given ”
A-Engrossed
“Gut and stuff” research tracks substantial replacements of a bill’s substantive text. Policy change is assessed separately: a rewrite can retain the same purpose. A proposed amendment is counted as adopted only when the official evidence supports adoption.
Two subscription subagents independently examine the same official evidence without seeing each other’s answers. An additional subagent can adjudicate disagreements against the sources. Unsupported conclusions, missing evidence, and unresolved disagreements remain uncertain. Agreement is not a guarantee of accuracy.
Session totals count each HB or SB once, including bills that did not become law. Resolutions and memorials are excluded. Counts describe the research inventory, independent of your search, interests, following, and status filters. Missing or unassessed bills are not negative findings.
The replacement watch is a rule, not an AI assessment: a bill whose introduced text is a short study bill (a study word, at most three sections, under 400 words) or a blank form (a run of blanks, 300 words or fewer) is listed once a proposed amendment is posted for it. In the 2021 to 2026 training sessions, 271 of 374 such bills were later replaced; the rate is historical and says nothing about a particular bill’s intent.
Assessments are published research snapshots. Opening this page reads saved research and does not run an AI review. Refreshes require another evidence export, independent assessment, and validated import; reports do not continuously refresh. Each bill’s evidence and reviewer provenance are available on its detail page.
Follow the official text for SB 1528 and every amendment branch. Connections come from each amendment's stated base. Horizontal position shows when each document was first posted, when available.
Click a card to isolate its connected lines; use View summary to jump to its details. Horizontal position shows first posting time in Pacific Time. Drag or use the arrow keys to pan. Pinch with two fingers on mobile, or zoom with the controls, +/− keys, or Control/Command + scroll; press 0 to reset. Dashed branches remained proposals.
Selected document summary
Substantial replacement
What the document says to change
Delete lines 4 through 8 and insert:
Oregon records no individual sponsors.
Presession filing record
Printed pursuant to Senate Interim Rule 213.28 by order of the President of the Senate in conformance with presession filing rules, indicating neither advocacy nor opposition on the part of the President.
LC 101 became SB 1528
Mapping document posted: January 6, 2026 at 2:16 PM PST
Work Session — <b>Introduction of Committee Legislative Concepts</b> <i>When available, LC drafts will be posted on the committee’s OLIS page.</i> LC 100 LC 101 LC 102
Senate Interim Committee on Health Care introduction work session
Committee meeting: January 13, 2026 at 2:30 PM PST
HR C
Committee introduction motion
Committee meeting: January 13, 2026 at 2:30 PM PST
A motion was made to adopt the listed legislative concepts as committee bills.
Official vote: 5-0-0
Committee introduction allows consideration; it does not imply every member supported the introduced or final text.
The text changed substantially while keeping measure number SB 1528.
Senate carrier
Senator Deb Patterson
Third Reading Of Senate Measures · Version A
A carrier presents the measure or report but is not necessarily its sponsor or author.
Records already listed in Activity are not repeated here.
27 events
Full timeline
27 entries shown.
In committee upon adjournment.
Public Hearing held.
Public Hearing
Heard · Agenda item 4 · Room HR D · Expands drug manufacturer annual reporting requirements to include all patient assistance programs offered or funded by the manufacturer that provided assistance to consumers in this state in the previous calendar year.
Referred to Rules.
First reading. Referred to Speaker's desk.
Third reading. Carried by Patterson. Passed.
Ayes, 17; Nays, 10--Anderson, Girod, Hayden, McLane, Meek, Nash, Robinson, Starr, Thatcher, Weber; Excused, 3--Drazan, Linthicum, Smith DB.
Second reading.
Senate Amendments to Introduced bill text posted
Recommendation: Do pass with amendments. (Printed A-Eng.)
Work Session held.
Work Session
Heard and Reported Out with Amendments · Agenda item 3 · Room HR D · CARRIED OVER FROM THE 02/11/2026 MEETING: Requires the Oregon Health Authority to study health care.
Amendment -MR5 minority report
IS_Impact SB 1528 2
Revenue Impact Statement
Amendment -3 proposed
Amendment -2 adopted
Public Hearing held.
Public Hearing
Heard · Agenda item 3 · Room HR D · Requires the Oregon Health Authority to study health care.
IS_Impact SB 1528 2
Revenue Impact Statement
Amendment -2 proposed
Amendment -3 proposed
Referred to Health Care.
Introduction and first reading. Referred to President's desk.
n’s Prescription Drug Price Transparency program was established within DCBS by House Bill 4005 (2019). The program is required to report to the legislature by December 15 eac
Source title: Expands drug manufacturer annual reporting requirements to include all patient assistance programs offered or funded by the manufacturer that provided assistance to consumers in this state in the previous calendar yearThis source title may describe an earlier version. Read the current brief and version history above.
“Expands drug manufacturer annual reporting requirements to include all patient assistance programs offered or funded by the manufacturer that provided assistance to consumers in this state in the previous calendar year.”
Confirm with the official record.
Supplemental, source-linked analysis from project researchers and community contributors. It is separate from Oregon's official record.